Transplantation 2001; 72: 1787 1792. 299. Rahn KH, Barenbrock M, Fritschka E et al. Effect of nitrendipine on renal function in renal-transplant patients treated with cyclosporin: a randomised trial. Lancet 1999; 354: 1415 1420. 300. van Riemsdijk IC, Mulder PG, de Fijter JW et al. Addition of isradipine (Lomir) results in a better renal function after kidney transplantation: a double-blind, randomized, placebo-controlled, multi-center study. Trans- plantation 2000; 70: 122 126. 301. Cross NB, Webster AC, Masson P et al. Antihypertensives for kidney transplant recipients: systematic review and meta-analysis of rando- mized controlled trials. Transplantation 2009; 88: 7 18. 302. Knoll GA, Blydt-Hansen TD, Campbell P et al. Canadian Society of Transplantation and Canadian Society of Nephrology commentary on the 2009 KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Kidney Dis 2010; 56: 219 246. 303. Olyaei AJ, de Mattos AM, Bennett WM. Nephrotoxicity of immunosup- pressive drugs: new insight and preventive strategies. Curr Opin Crit Care 2001; 7: 384 389. 304. Dawson KL, Patel SJ, Putney D et al. Cardioprotective medication use after renal transplantation. Clin Transplant 2010; 24: E253 E256. 305. Hiremath S, Fergusson D, Doucette S et al. Renin angiotensin system blockade in kidney transplantation: a systematic review of the evidence. Am J Transplant 2007; 7: 2350 2360. 306. Heinze G, Mitterbauer C, Regele H et al. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol 2006; 17: 889 899. 307. Opelz G, Zeier M, Laux G et al. No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers: a collaborative transplant study report. J Am Soc Nephrol 2006; 17: 3257 3262. 